A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

NCT01294631 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Canagliflozin 300 mg once daily and HCTZ 25 mg once daily

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.